These clinical studies suggested that adoptive transfer of autologous or allogenic Vγ9Vδ2 T cell not only exert direct γδ T cell-mediated anti-tumor effect, but also promote and rescue the anti-tumor capacity of CD4+ and CD8+ T cells, suggesting a promising immunotherapeutic strategy. The gene discussed is CD4; the disease is neoplasm.